Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

GRAL

G

GRAIL, Inc. (GRAL)

NMS – Цена в реальном времени. Валюта: USD

48.49

-3.67 (-7.04%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

48.30

-0.19 (-0.39%)

После закрытия: Mar 27, 2026, 7:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Here's Why Grail Stock Soared Higher This Week

Here's Why Grail Stock Soared Higher This Week

Investors are hoping follow-up trial data will validate Grail's Galleri test. The failure to meet a trial's primary endpoint could be due to how the trial was designed rather than the efficacy of the Galleri test.

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, March 25, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights.

This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month

This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month

One Fin Capital sold 380,000 shares of GRAIL in the fourth quarter. The quarter-end position value declined by $22.47 million as a result of the sale.

Here's Why Grail Shares Crushed the Market This Week

Here's Why Grail Shares Crushed the Market This Week

The probability that the company will receive FDA approval and insurance coverage for its Galleri test might justify buying the stock at current levels. Management hopes folllow up data from its three-year trial of Galleri

LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED

LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED

Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time NEW YORK, March 18, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial failed to meet its primary endpoint. Shareholders who lost money on GRAL are encouraged to submit their information now.

Grail CEO Bob Ragusa to retire, Josh Ofman named successor

Grail CEO Bob Ragusa to retire, Josh Ofman named successor

Cancer test maker Grail said on Thursday that chief executive Bob Ragusa will retire effective June 1, and the company's ‌president, Josh Ofman, will take over the helm.

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026.

Видео

Trump Media CEO: 'NUCLEAR FUSION is the HOLY GRAIL'

Пресс-релизы

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, March 25, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights.

LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED

LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED

Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time NEW YORK, March 18, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial failed to meet its primary endpoint. Shareholders who lost money on GRAL are encouraged to submit their information now.

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026.

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time